Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2022 11:39 ET | Source: GigaGen, Inc.

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development

SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and...
September 30, 2021 10:17 ET | Source: GigaGen, Inc.

GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
August 11, 2021 10:26 ET | Source: GigaGen, Inc.

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
July 14, 2021 10:00 ET | Source: GigaGen, Inc.

GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564

--Reduced checkpoint inhibitor activity of GIGA-564 versus current anti-CTLA-4 inhibitors results in superior anti-tumor activity and lower toxicity in murine models ----Data supports advancement of...
May 25, 2021 10:15 ET | Source: GigaGen, Inc.

GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies

SOUTH SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint...
April 15, 2021 11:59 ET | Source: GigaGen, Inc.

GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology

SOUTH SAN FRANCISCO, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
March 23, 2021 10:00 ET | Source: GigaGen, Inc.

GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant...
October 20, 2020 10:17 ET | Source: GigaGen, Inc.

GigaGen Announces Publication in the Peer-Reviewed Journal mAbs

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
September 09, 2020 10:17 ET | Source: GigaGen, Inc.

GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and...
August 10, 2020 10:17 ET | Source: GigaGen, Inc.

GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050

GIGA-2050 is like a "recombinant convalescent serum," enabling production of millions of doses of drug from a few donorsGIGA-2050 is 100-fold more potent than convalescent serum and comprises 12,500...